*	OR T7 T6
R1	Has_multiplier Arg1:T9 Arg2:T8	
R2	Has_qualifier Arg1:T5 Arg2:T7	
R3	Has_value Arg1:T3 Arg2:T4	
*	OR T1 T2
R4	AND Arg1:T5 Arg2:T9	
R5	Subsumes Arg1:T12 Arg2:T13	
R6	Has_value Arg1:T12 Arg2:T14	
T1	Person 0 4	Male
T2	Person 8 14	female
T3	Person 24 27	age
T4	Value 28 45	18 years or older
T5	Condition 75 80	sALCL
T6	Qualifier 64 74	refractory
T7	Qualifier 52 60	relapsed
T8	Multiplier 110 120	at least 1
T9	Procedure 132 144	chemotherapy
T11	Non-query-able 146 178	Bidimensional measurable disease
T12	Measurement 183 217;225 243	Eastern Cooperative Oncology Group performance status
T13	Measurement 219 223	ECOG
T14	Value 247 253	0 or 1
T15	Pregnancy_considerations 255 577	Female patients who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 30 days after the last dose of study drug, or agree to practice true abstinence
T16	Pregnancy_considerations 579 775	Male patients who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence
T17	Non-query-able 777 838	Clinical laboratory values as specified in the study protocol
